June 2019 - Volume 3 - Issue S1 - Contributor Index

PF419 ANALYSIS OF THE INFLUENCE OF AGE ON MAJOR MOLECULAR RESPONSE,DEEP MOLECULAR RESPONSE AND SURVIVAL OUTCOMES IN CHRONIC MYELOID LEUKEMIA (CML) PATIENTS TREATED WITH TYROSINE KINASE INHIBITORS (TKIS)

Casado Montero, L.F.; García-Ormeña, N.; J Valentín, G.-G.; More

HemaSphere. 3(S1):162-163, June 2019.

Author:
Jabbour, E.

PF205 RNA BASED IMMUNE SIGNATURES MAY PREDICT RESPONSES TO PD-1 INHIBITION AND AZACITIDINE TREATMENT IN ACUTE MYELOID LEUKEMIA (AML): A SUBSET ANALYSIS OF A PHASE 2 STUDY

Abbas, H.; Alfayez, M.; Wang, F.; More

HemaSphere. 3(S1):54-55, June 2019.

PF212 NEXT-GENERATION SEQUENCING OF CIRCULATING CELL-FREE DNA PROVIDES COMPLEMENTARY INFORMATION TO GENOMIC PROFILING OF BONE MARROW IN PATIENTS WITH ACUTE LEUKEMIAS

Short, N.; Patel, K.; Albitar, M.; More

HemaSphere. 3(S1):58, June 2019.

PF673 PHASE 1/2 STUDY OF RUXOLITINIB (RUX) PLUS DECITABINE (DAC) IN PATIENTS (PTS) WITH POST-MYELOPROLIFERATIVE NEOPLASM ACUTE MYELOID LEUKEMIA (POST-MPN AML)

Bose, P.; Verstovsek, S.; Naqvi, K.; More

HemaSphere. 3(S1):289-290, June 2019.

S829 SOTATERCEPT (ACE-011) IN SUBJECTS WITH MPN-ASSOCIATED MYELOFIBROSIS AND ANEMIA

Bose, P.; Pemmaraju, N.; Daver, N.; More

HemaSphere. 3(S1):367-368, June 2019.

S833 THE SINGLE-CELL ATLAS OF DRIVER MUTATIONS IN AML

Morita, K.; Wang, F.; Jahn, K.; More

HemaSphere. 3(S1):370, June 2019.

PS940 COMBINATION BCL-2 INHIBITOR THERAPY WITH VENETOCLAX AND NAVITOCLAX IN PATIENTS WITH RELAPSED/REFRACTORY ACUTE LYMPHOBLASTIC LEUKEMIA AND LYMPHOBLASTIC LYMPHOMA

Pullarkat, V.A.; Stock, W.; Lacayo, N.J.; More

HemaSphere. 3(S1):423-424, June 2019.

PS949 INOTUZUMAB OZOGAMICIN (INO) TREATMENT IN PATIENTS WITH RELAPSED/REFRACTORY ACUTE LYMPHOBLASTIC LEUKEMIA (R/R ALL): OUTCOMES OF PATIENTS TREATED IN SALVAGE ONE WITH A LONG DURATION OF FIRST REMISSION

Stelljes, M.; Jabbour, E.; Advani, A.; More

HemaSphere. 3(S1):427-428, June 2019.

PS950 EFFICACY AND SAFETY OF INOTUZUMAB OZOGAMICIN IN PATIENTS WITH RELAPSED/REFRACTORY B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA TREATED IN THE INO-VATE TRIAL: OUTCOMES BY SALVAGE-TREATMENT PHASE

Jabbour, E.; Stelljes, M.; Advani, A.S.; More

HemaSphere. 3(S1):428, June 2019.

PS1064 EXPLORATORY ANALYSIS OF OUTCOMES WITH SEQUENTIAL FLT3-INHIBITOR (FLT3I) BASED THERAPIES IN RELAPSED FLT3-MUTATED AML PATIENTS (PTS)

Alfayez, M.; Kantarjian, H.; Ravandi, F.; More

HemaSphere. 3(S1):481-482, June 2019.

PS1180 FOLLOW-UP OF LOWER DOSE DASATINIB 50MG DAILY AS FRONTLINE THERAPY IN NEWLY DIAGNOSED CHRONIC PHASE CHRONIC MYELOID LEUKEMIA (CML-CP)

Naqvi, K.; Jabbour, E.; Skinner, J.; More

HemaSphere. 3(S1):537, June 2019.

S1615 SAFETY, EFFICACY, AND BIOMARKERS OF RESPONSE TO AZACITIDINE (AZA) WITH NIVOLUMAB (NIVO) AND IPILIMUMAB (IPI), AND AZA WITH NIVO IN R/R ACUTE MYELOID LEUKEMIA: A NON-RANDOMIZED, PHASE 2 STUDY.

Daver, N.; Alfayez, M.; Garcia-Manero, G.; More

HemaSphere. 3(S1):745, June 2019.

PB1722 IMPACT OF CD33 AND ABCB1 SINGLE NUCLEOTIDE POLYMORPHISMS IN PATIENTS WITH ACUTE MYELOID LEUKEMIA AND HIGH-RISK MYELODYSPLASTIC SYNDROMES TREATED WITH DECITABINE PLUS GEMTUZUMAB OZOGAMICIN

Short, N.; Richard-Carpentier, G.; Kanagal-Shamanna, R.; More

HemaSphere. 3(S1):791-792, June 2019.

Author:
Jabeur, D.
Author:
Jablonska, E.

PF524 EVALUATION OF SERINE BIOSYNTHESIS PATHWAY AS A POTENTIAL THERAPEUTIC TARGET IN BURKITT LYMPHOMA

Noyszewska-Kania, M.; Bialopiotrowicz, E.; Cybulska, M.; More

HemaSphere. 3(S1):214-215, June 2019.

PS986 SYK-DEPENDENT P-STAT5 ACTIVITY IS REQUIRED TO MAINTAIN CLONOGENIC POTENTIAL AND OXPHOS METABOLISM IN ACUTE MYELOID LEUKEMIA (AML) CELLS

Polak, A.; Bialopiotrowicz, E.; Jablonska, E.; More

HemaSphere. 3(S1):443, June 2019.

Author:
Jabr, D.
Author:
Jaccard, A.

S103 OBINUTUZUMAB PLUS DHAP FOLLOWED BY AUTOLOGOUS STEM CELL TRANSPLANTATION PLUS OBINUTUZUMAB MAINTENANCE PROVIDES A HIGH MRD RESPONSE RATE IN UNTREATED MCL PATIENTS, LYMA-101 TRIAL - A LYSA TRIAL

Legouill, S.; Beldi-Ferchiou, A.; Cacheux, V.; More

HemaSphere. 3(S1):3, June 2019.

PF603 FASTER & SUSTAINED IMPROVEMENT IN HEALTH-RELATED QUALITY OF LIFE IN TRANSPLANT-INELIGIBLE NEWLY DIAGNOSED MULTIPLE MYELOMA PTS TREATED WITH DARATUMUMAB, LENALIDOMIDE & DEXAMETHASONE (D-RD) VS RD: MAIA

Perrot, A.; Facon, T.; Plesner, T.; More

HemaSphere. 3(S1):255, June 2019.

PS1377 IMPROVEMENT IN HEALTH-RELATED QUALITY OF LIFE FOR NEWLY DIAGNOSED MULTIPLE MYELOMA TRANSPLANT-ELIGIBLE PATIENTS TREATED WITH DARATUMUMAB, BORTEZOMIB, THALIDOMIDE, AND DEXAMETHASONE: CASSIOPEIA STUDY

Roussel, M.; Moreau, P.; Attal, M.; More

HemaSphere. 3(S1):630, June 2019.

PB2117 POMALIDOMIDE PLUS LOW-DEXAMETHASONE TREATMENT FOR ≥ 1 YEAR IN PATIENTS WITH RELAPSED REFRACTORY MULTIPLE MYELOMA AND RENAL IMPAIRMENT: A SUBANALYSIS OF THE MM-013 PHASE 2 STUDY

Weisel, K.; Dimopoulos, M.; Cook, M.; More

HemaSphere. 3(S1):953, June 2019.

Author:
Jachimowski, L.
Author:
Jack, F.

PF691 SPLENECTOMY IN IMMUNE THROMBOCYTOPENIA: DO CHANGING TREATMENT PATTERNS FOR ITP AFFECT OUTCOMES? DATA FROM THE UK ITP REGISTRY

Todd, S.; Infirri, S. Sardo; Miah, H.; More

HemaSphere. 3(S1):299-300, June 2019.

Author:
Jackson, G.

S873 EFFICACY OF QUADRUPLET KCRD (CARFILZOMIB, CYCLOPHOSPHAMIDE, LENALIDOMIDE AND DEXAMETHASONE) INDUCTION FOR NEWLY DIAGNOSED MYELOMA PATIENTS: ANALYSIS OF THE MYELOMA XI STUDY BY MOLECULAR RISK

Pawlyn, C.; Kaiser, M.; Davies, F.; More

HemaSphere. 3(S1):391, June 2019.

Author:
Jackson, H.

PF558 THE ANTI-BCMA ANTIBODY-DRUG CONJUGATE GSK2857916 DRIVES IMMUNOGENIC CELL DEATH AND IMMUNE-MEDIATED ANTI-TUMOR RESPONSES, AND IN COMBINATION WITH AN OX40 AGONIST POTENTIATES IN VIVO ACTIVITY

Montes De Oca, R.; Bhattacharya, S.; Vitali, N.; More

HemaSphere. 3(S1):231, June 2019.

PF691 SPLENECTOMY IN IMMUNE THROMBOCYTOPENIA: DO CHANGING TREATMENT PATTERNS FOR ITP AFFECT OUTCOMES? DATA FROM THE UK ITP REGISTRY

Todd, S.; Infirri, S. Sardo; Miah, H.; More

HemaSphere. 3(S1):299-300, June 2019.

Author:
Jackson, J.
Author:
Jacob, J.
Author:
Jacobs, K.
Author:
Jacobs, L.
Author:
Jacobsen, E.

S869 TIPIFARNIB IN RELAPSED OR REFRACTORY ANGIOIMMUNOBLASTIC T-CELL LYMPHOMA (AITL) AND CXCL12+ PERIPHERAL T-CELL LYMPHOMA (PTCL): PRELIMINARY RESULTS FROM AN OPEN-LABEL, PHASE 2 STUDY

Witzig, T.; Sokol, L.; Kim, W.S.; More

HemaSphere. 3(S1):389, June 2019.

Author:
Jacobson, A.

PS940 COMBINATION BCL-2 INHIBITOR THERAPY WITH VENETOCLAX AND NAVITOCLAX IN PATIENTS WITH RELAPSED/REFRACTORY ACUTE LYMPHOBLASTIC LEUKEMIA AND LYMPHOBLASTIC LYMPHOMA

Pullarkat, V.A.; Stock, W.; Lacayo, N.J.; More

HemaSphere. 3(S1):423-424, June 2019.

Author:
Jacobson, C.A.

PF374 IBRUTINIB PLUS FLUDARABINE, CYCLOPHOSPHAMIDE, AND RITUXIMAB (IFCR) AS INITIAL THERAPY FOR YOUNGER PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA: A SINGLE-ARM, MULTICENTER, PHASE 2 TRIAL

Davids, M.S.; Brander, D.M.; Kim, H.T.; More

HemaSphere. 3(S1):138-139, June 2019.

PS1066 AXICABTAGENE CILOLEUCEL (AXI-CEL) IN REFRACTORY LARGE B CELL LYMPHOMA: OUTCOMES IN PATIENTS ≥ OR < 65 YEARS OF AGE IN THE PIVOTAL PHASE 1/2 ZUMA-1 STUDY

Neelapu, S.S.; Jacobson, C.A.; Oluwole, O.O.; More

HemaSphere. 3(S1):482-483, June 2019.

Author:
Jacomy, D.

PF373 IMPACT OF ATM ALTERATIONS ON CHRONIC LYMPHOCYTIC LEUKEMIA IN GENERAL PRACTICE IN THE AREA OF NEXT GENERATION SEQUENCING

Ganard, M.; Houot, R.; Henry, C.; More

HemaSphere. 3(S1):137-128, June 2019.

Author:
Jacopo, P.

PS1061 ELDERLY PATIENTS WITH DE NOVO OR SECONDARY AML HAVE COMPARABLE OUTCOMES AFTER INTENSIVE TREATMENTS INCLUDING HIGH DOSE (HD) CYTARABINE AND AUTOLOGOUS (AUTO) OR ALLOGENEIC (ALLO) TRANSPLANTATION (SCT)

Bernardi, M.S.; Carrabba, M.G.; Pavesi, F.; More

HemaSphere. 3(S1):480, June 2019.

Author:
Jacqmin, H.
Author:
Jacqmin, P.
Author:
Jacques, C.

PF608 ANCHOR (OP-104): A PHASE 1 STUDY UPDATE OF MELFLUFEN AND DEXAMETHASONE PLUS BORTEZOMIB OR DARATUMUMAB IN RELAPSED/REFRACTORY MULTIPLE MYELOMA PATIENTS REFRACTORY TO AN IMID OR A PROTEASOME INHIBITOR

Pour, L.; Efebera, Y.A.; Granell, M.; More

HemaSphere. 3(S1):257-258, June 2019.

Author:
Jae, P.

S1634 A PHASE I FIRST-IN-HUMAN CLINICAL TRIAL OF CD19-TARGETED 19–28Z/4–1BBL “ARMORED” CAR T CELLS IN PATIENTS WITH RELAPSED OR REFRACTORY NHL AND CLL INCLUDING RICHTER TRANSFORMATION

Palomba, M.L.; Batlevi, C.; Riviere, I.; More

HemaSphere. 3(S1):755, June 2019.

Author:
Jaeger, E.

S888 TNF-ALPHA PROMOTES CLONAL EXPANSION OF KIT D816V+ CELLS IN SYSTEMIC MASTOCYTOSIS

Greiner, G.; Witzeneder, N.; Klein, K.; More

HemaSphere. 3(S1):399-400, June 2019.

Author:
Jaeger, U.
Author:
Jaekel, N.
Author:
Jagannath, S.

PS1384 TREATMENT CHOICES AND OUTCOMES FOR PATIENTS WITH MULTIPLE MYELOMA AFTER RELAPSE ON LENALIDOMIDE MAINTENANCE THERAPY: RESULTS FROM THE CONNECT® MM REGISTRY

Jagannath, S.; Narang, M.; Ailawadhi, S.; More

HemaSphere. 3(S1):634, June 2019.

Author:
Jagasia, M.

PS1533 KD025–208: A PHASE 2A TRIAL OF KD025 FOR PATIENTS WITH CHRONIC GRAFT-VERSUS-HOST DISEASE (CGVHD) – UPDATED SAFETY AND EFFICACY

Salhotra, A.; Zoghi, B.; Essell, J.; More

HemaSphere. 3(S1):707-708, June 2019.

Author:
Jagdhane, P.
Author:
Jager, A.

PS938 INTENSIVE PAEDIATRIC THERAPY IS AS DELIVERABLE IN ADOLESCENTS AND YOUNG ADULTS AS CHILDREN WITH ALL - PRELIMINARY RESULTS OF THE AUSTRALASIAN LEUKAEMIA AND LYMPHOMA GROUP (ALLG) ALL06 STUDY

Greenwood, M.; Trahair, T.; Osborn, M.; More

HemaSphere. 3(S1):422, June 2019.

Author:
Jäger, E.

PS1331 MYELOMONOCYTIC SKEWING IN CHRONIC MYELOMONOCYTIC LEUKEMIA: PHENOTYPIC, GENOTYPIC AND BIOLOGIC FEATURES AND IMPACT ON SURVIVAL

Geissler, K.; Jäger, E.; Barna, A.; More

HemaSphere. 3(S1):607-608, June 2019.

Author:
Jäger, R.

PS1436 IFN-Α TREATMENT NORMALIZES THE PLATELET COUNTS AND REDUCES QUIESCENT STEM CELLS IN A CALR-DEL52 TRANSGENIC MOUSE MODEL, IN VIVO

Nivarthi, H.; Majoros, A.; Hug, E.; More

HemaSphere. 3(S1):662, June 2019.

Author:
Jäger, U.

PS1157 EFFECT OF DOSE MODIFICATIONS ON RESPONSE TO DUVELISIB IN PATIENTS WITH RELAPSED/REFRACTORY CLL/SLL IN THE DUO TRIAL

Ghia, P.; Flinn, I.; Lamanna, N.; More

HemaSphere. 3(S1):525, June 2019.

PS1331 MYELOMONOCYTIC SKEWING IN CHRONIC MYELOMONOCYTIC LEUKEMIA: PHENOTYPIC, GENOTYPIC AND BIOLOGIC FEATURES AND IMPACT ON SURVIVAL

Geissler, K.; Jäger, E.; Barna, A.; More

HemaSphere. 3(S1):607-608, June 2019.

Author:
Jaggia, A.

PF691 SPLENECTOMY IN IMMUNE THROMBOCYTOPENIA: DO CHANGING TREATMENT PATTERNS FOR ITP AFFECT OUTCOMES? DATA FROM THE UK ITP REGISTRY

Todd, S.; Infirri, S. Sardo; Miah, H.; More

HemaSphere. 3(S1):299-300, June 2019.

Author:
Jaglowski, S.
Author:
Jagurinoski, M.
Author:
Jahn, K.

S833 THE SINGLE-CELL ATLAS OF DRIVER MUTATIONS IN AML

Morita, K.; Wang, F.; Jahn, K.; More

HemaSphere. 3(S1):370, June 2019.

Author:
Jahn, L.
Author:
Jahn, N.

PF260 PROGNOSTIC AND PREDICTIVE IMPACT OF NPM1/FLT3-ITD GENOTYPES AS DEFINED BY 2017 EUROPEAN LEUKEMIANET RISK CATEGORIZATION FROM AML PATIENTS TREATED WITHIN THE INTERNATIONAL RATIFY STUDY

Döhner, K.; Thiede, C.; Jahn, N.; More

HemaSphere. 3(S1):81-82, June 2019.

PS968 GENETIC LANDSCAPE OF FLT3-MUTATED ACUTE MYELOID LEUKEMIA (AML) PATIENTS TREATED WITHIN THE RATIFY TRIAL: CALGB 10603 (ALLIANCE)

Jahn, N.; Panina, E.; Bullinger, L.; More

HemaSphere. 3(S1):436, June 2019.

S1616 MEASURABLE RESIDUAL DISEASE MONITORING IN ACUTE MYELOID LEUKEMIA (AML) WITH T(8;21)(Q22;Q22.1); RUNX1-RUNX1T1: RESULTS OF THE AML STUDY GROUP (AMLSG)

Rücker, F.G.; Agrawal, M.; Corbacioglu, A.; More

HemaSphere. 3(S1):745-746, June 2019.

Author:
Jahnukainen, K.

PF677 DNA HYPERMETHYLATION EMERGES AS THE STRONGEST PREDICTOR FOR POOR OUTCOME AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN JUVENILE MYELOMONOCYTIC LEUKEMIA (JMML)

Niemeyer, C.M.; Flotho, C.; Lipka, D.B.; More

HemaSphere. 3(S1):292, June 2019.

Author:
Jahreis, A.

PF348 LONG TERM FOLLOW-UP OF PNH PATIENTS TREATED WITH THE SMART ANTI-HC5 ANTIBODY (SKY59/RO7112689) IN THE OPEN LABEL EXTENSION (OLE) OF THE COMPOSER TRIAL

Röth, A.; Nagy, Z.; Peffault de Latour, R.; More

HemaSphere. 3(S1):125-126, June 2019.

Author:
Jain, A.

PF498 A PHASE 2, RANDOMIZED, CONTROLLED, OPEN-LABEL TRIAL OF DAILY VERSUS ALTERNATE DAY ORAL IRON IN TREATMENT OF IRON DEFICIENCY ANEMIA

Lad, D.P.; Kaundal, R.; Bhatia, P.; More

HemaSphere. 3(S1):201-202, June 2019.

PF498 A PHASE 2, RANDOMIZED, CONTROLLED, OPEN-LABEL TRIAL OF DAILY VERSUS ALTERNATE DAY ORAL IRON IN TREATMENT OF IRON DEFICIENCY ANEMIA

Lad, D.P.; Kaundal, R.; Bhatia, P.; More

HemaSphere. 3(S1):201-202, June 2019.

Author:
Jain, N.

PF673 PHASE 1/2 STUDY OF RUXOLITINIB (RUX) PLUS DECITABINE (DAC) IN PATIENTS (PTS) WITH POST-MYELOPROLIFERATIVE NEOPLASM ACUTE MYELOID LEUKEMIA (POST-MPN AML)

Bose, P.; Verstovsek, S.; Naqvi, K.; More

HemaSphere. 3(S1):289-290, June 2019.

PS1180 FOLLOW-UP OF LOWER DOSE DASATINIB 50MG DAILY AS FRONTLINE THERAPY IN NEWLY DIAGNOSED CHRONIC PHASE CHRONIC MYELOID LEUKEMIA (CML-CP)

Naqvi, K.; Jabbour, E.; Skinner, J.; More

HemaSphere. 3(S1):537, June 2019.

Author:
Jain, P.
Author:
Jain, R.

PS962 PHASE 1 RESULTS OF ZUMA-4: KTE-X19, AN ANTI-CD19 CHIMERIC ANTIGEN RECEPTOR T CELL THERAPY, IN PEDIATRIC AND ADOLESCENT PATIENTS WITH RELAPSED/REFRACTORY B CELL ACUTE LYMPHOBLASTIC LEUKEMIA

Wayne, A.S.; Huynh, V.; Hijiya, N.; More

HemaSphere. 3(S1):433, June 2019.

Author:
Jain, R.K.